GR1007516B - Φαρμακο για την θεραπεια της νοσου της ψωριασης - Google Patents

Φαρμακο για την θεραπεια της νοσου της ψωριασης

Info

Publication number
GR1007516B
GR1007516B GR20100100426A GR20100100426A GR1007516B GR 1007516 B GR1007516 B GR 1007516B GR 20100100426 A GR20100100426 A GR 20100100426A GR 20100100426 A GR20100100426 A GR 20100100426A GR 1007516 B GR1007516 B GR 1007516B
Authority
GR
Greece
Prior art keywords
psoriasis
medicine
treatment
novelty
symptoms
Prior art date
Application number
GR20100100426A
Other languages
English (en)
Inventor
Χρηστος Νικολαου Γκιλιτσης
Φιλοκτητης Γεωργιου Διακομανωλης
Original Assignee
Χρηστος Νικολαου Γκιλιτσης
Φιλοκτητης Γεωργιου Διακομανωλης
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Χρηστος Νικολαου Γκιλιτσης, Φιλοκτητης Γεωργιου Διακομανωλης filed Critical Χρηστος Νικολαου Γκιλιτσης
Priority to GR20100100426A priority Critical patent/GR1007516B/el
Priority to PCT/GR2011/000031 priority patent/WO2012013990A2/en
Publication of GR1007516B publication Critical patent/GR1007516B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Προϊόντα που περιέχουν δραστική ουσία losartan potassium, για χρήση στην θεραπεία της νόσου της ψωρίασης. Η χορήγηση, σκευάσματος περιέχοντος δραστική ουσία losartan potassium σε δοσολογία 100, milligram ημερησίως, σε πάσχοντες από την νόσο της ψωρίασης, είχε σαν αποτέλεσμα την εξαφάνιση όλων των συμπτωμάτων της νόσου.
GR20100100426A 2010-07-30 2010-07-30 Φαρμακο για την θεραπεια της νοσου της ψωριασης GR1007516B (el)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GR20100100426A GR1007516B (el) 2010-07-30 2010-07-30 Φαρμακο για την θεραπεια της νοσου της ψωριασης
PCT/GR2011/000031 WO2012013990A2 (en) 2010-07-30 2011-08-01 Medication for curing the disease of psoriasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20100100426A GR1007516B (el) 2010-07-30 2010-07-30 Φαρμακο για την θεραπεια της νοσου της ψωριασης

Publications (1)

Publication Number Publication Date
GR1007516B true GR1007516B (el) 2012-01-24

Family

ID=44872431

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20100100426A GR1007516B (el) 2010-07-30 2010-07-30 Φαρμακο για την θεραπεια της νοσου της ψωριασης

Country Status (2)

Country Link
GR (1) GR1007516B (el)
WO (1) WO2012013990A2 (el)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137556A1 (en) * 2004-08-18 2009-05-28 Ace Aps Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists

Also Published As

Publication number Publication date
WO2012013990A3 (en) 2012-03-15
WO2012013990A2 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12015502839A1 (en) Antiviral compounds
MY163083A (en) Solid forms of a pharmaceutically active substance
GEP20166438B (en) Imidazopyrrolidinone compounds
SG190785A1 (en) Antiviral compounds
PH12014502613A1 (en) Synthesis of heterocyclic compound
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
GB201106743D0 (en) Novel compounds
MX392150B (es) Moduladores de receptores canabinoides.
GEP201706710B (en) Imidazopyridazine derivatives as gabaa receptor modulators
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
IN2015DN01119A (el)
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
EP4360621A3 (en) Formulations of bendamustine
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
GEP201706621B (en) Benzamides
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
EA201400444A1 (ru) Производные 2-оксопиперидинила
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
IN2014DN03010A (el)
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents
MX348147B (es) Biarilsulfonamidas utiles en el tratamiento de la inflamacion y cancer.

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20120305

ML Lapse due to non-payment of fees

Effective date: 20130104